Subcutaneous bispecific T‑cell–engaging monoclonal antibody targeting CD3 on T cells and CD20 on B cells to drive targeted T‑cell–mediated cytotoxicity.
Bispecific monoclonal antibody that simultaneously binds CD3 on T cells and CD20 on B cells, cross-linking T cells to CD20+ malignant B cells to form an immune synapse and activate T-cell–mediated cytotoxicity (perforin/granzyme release) against the target B cells.
YES
DIRECT
Epcoritamab crosslinks CD3 on T cells to CD20 on target cells, forming an immune synapse and inducing perforin/granzyme-mediated T-cell killing of CD20+ cells.
Subcutaneous bispecific T‑cell–engaging monoclonal antibody targeting CD3 on T cells and CD20 on B cells to drive targeted T‑cell–mediated cytotoxicity.
Bispecific monoclonal antibody that simultaneously binds CD3 on T cells and CD20 on B cells, cross-linking T cells to CD20+ malignant B cells to form an immune synapse and activate T-cell–mediated cytotoxicity (perforin/granzyme release) against the target B cells.
NO
INDIRECT
Epcoritamab binds CD3 on T cells to activate them and simultaneously binds CD20 on B cells, leading T cells to kill CD20+ B cells via perforin/granzyme; CD3+ cells are effectors, not targets.
Anti‑CD20 monoclonal antibody that depletes B cells via ADCC, complement-dependent cytotoxicity, and induction of apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive malignant and normal B cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and its Fc region recruits immune effectors to induce ADCC and complement-dependent cytotoxicity; crosslinking can also trigger apoptosis.
An intravenous MAT-Fab bispecific T-cell–engaging antibody that binds CD3 on T cells and ROR1 on tumor cells to redirect cytotoxic T lymphocytes against ROR1-positive cancers.
EMB-07 is a bispecific antibody that simultaneously binds CD3 on T cells and ROR1 on tumor cells, bringing cytotoxic T lymphocytes into close proximity with ROR1-positive cancer cells to trigger TCR/CD3 activation and perforin/granzyme-mediated tumor cell killing.
YES
DIRECT
EMB-07 links CD3 on T cells to ROR1 on tumor cells, activating CTLs to kill ROR1+ cells via perforin/granzyme-mediated cytotoxicity.
An intravenous MAT-Fab bispecific T-cell–engaging antibody that binds CD3 on T cells and ROR1 on tumor cells to redirect cytotoxic T lymphocytes against ROR1-positive cancers.
EMB-07 is a bispecific antibody that simultaneously binds CD3 on T cells and ROR1 on tumor cells, bringing cytotoxic T lymphocytes into close proximity with ROR1-positive cancer cells to trigger TCR/CD3 activation and perforin/granzyme-mediated tumor cell killing.
NO
INDIRECT
EMB-07 crosslinks CD3 on T cells with ROR1 on tumor cells, activating T cells to kill ROR1-positive cancer cells via perforin/granzyme; CD3+ T cells themselves are not targeted for killing.